BACKGROUND With programmed death-1(PD-1) inhibitors becoming the standard treatment for lung cancer,PD-1-related adverse reactions and treatment have gradually become prominent.CASE SUMMARY First reported case of tisl...BACKGROUND With programmed death-1(PD-1) inhibitors becoming the standard treatment for lung cancer,PD-1-related adverse reactions and treatment have gradually become prominent.CASE SUMMARY First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles.The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms,abdominal computed tomography and colonoscopy improved,significant diarrhea was not occurred.CONCLUSION Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.展开更多
To the Editor:A 58-year-old man,who diagnosed with chronic myelomonocytic leukemia in June 2019,achieved complete bone marrow remission after five courses of chemotherapy(decitabine 35 mg,days 1–5).In December 2019,h...To the Editor:A 58-year-old man,who diagnosed with chronic myelomonocytic leukemia in June 2019,achieved complete bone marrow remission after five courses of chemotherapy(decitabine 35 mg,days 1–5).In December 2019,he underwent an allogeneic hematopoietic stem cell transplant(allo-HSCT)from his human leukocyte antigen-haploidentical daughter.The donor and host pre-trans-plant Epstein-Barr virus(EBV)serologies were negative.The myeloablative conditioning regimen was administered with cytarabine,busulfan,cyclophosphamide,methyl-N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea,and anti-thy-mocyte globulin.The numbers of mononuclear cells and CD34+cells were 12.23108/kg and 7.57108/kg,respectively.Graft-versus-host disease(GVHD)prophy-laxis included cyclosporin A(CSA)and mycophenolate mofetil(MMF).CSA was later changed to tacrolimus due to a gastrointestinal reaction on day+15.The patient had a history of tuberculosis(TB)and received isoniazid and rifapentine for prevention.Neutrophil and platelet engraftment occurred on day+12 and+18,respectively.Cytogenetic studies showed complete donor chimerism on day+26.展开更多
文摘BACKGROUND With programmed death-1(PD-1) inhibitors becoming the standard treatment for lung cancer,PD-1-related adverse reactions and treatment have gradually become prominent.CASE SUMMARY First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles.The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms,abdominal computed tomography and colonoscopy improved,significant diarrhea was not occurred.CONCLUSION Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.
文摘To the Editor:A 58-year-old man,who diagnosed with chronic myelomonocytic leukemia in June 2019,achieved complete bone marrow remission after five courses of chemotherapy(decitabine 35 mg,days 1–5).In December 2019,he underwent an allogeneic hematopoietic stem cell transplant(allo-HSCT)from his human leukocyte antigen-haploidentical daughter.The donor and host pre-trans-plant Epstein-Barr virus(EBV)serologies were negative.The myeloablative conditioning regimen was administered with cytarabine,busulfan,cyclophosphamide,methyl-N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea,and anti-thy-mocyte globulin.The numbers of mononuclear cells and CD34+cells were 12.23108/kg and 7.57108/kg,respectively.Graft-versus-host disease(GVHD)prophy-laxis included cyclosporin A(CSA)and mycophenolate mofetil(MMF).CSA was later changed to tacrolimus due to a gastrointestinal reaction on day+15.The patient had a history of tuberculosis(TB)and received isoniazid and rifapentine for prevention.Neutrophil and platelet engraftment occurred on day+12 and+18,respectively.Cytogenetic studies showed complete donor chimerism on day+26.
